Dr. Robert H. Vonderheide
PHILADELPHIA – A promising class of drugs known as CD40 monoclonal antibodies could be the spark needed to light the fire in the immune system of patients who don’t respond to the newer cancer immunotherapies.
Robert H. Vonderheide, MD, DPhil, director of the Abramson Cancer Center at the University of Pennsylvania and an internationally renowned cancer immunotherapy expert, makes the case for the drugs in a new perspective piece published this week in Cancer Cell, as part of a series in the issue focusing on the next phase of the evolving field of cancer immunotherapy.
“The ‘immuno revolution’ is upon us: We’re battling cancers like never before by tapping into the power of the immune system with checkpoint inhibitors and personalized cellular therapies that have elicited stellar responses in patients,” Vonderheide said. “But there is a bittersweet quality to these successes: many patients do not respond or quickly relapse after an initial response.”
The PD-1 antibody pembrolizumab, for example, is approved for use as a first-line therapy for patients with metastatic non-small cell lung cancer that overexpresses PD-L1, which cancer cells use to hide from the immune system, yet nearly 30 percent of patients don’t respond to the therapy and another 25 percent have tumor progression at one year.
“To overcome the resistance in these patients, we need to go back to the beginning and prime the T cells before we jumpstart their immune system with other therapies to attack the cancer,” Vonderheide said.
The CD40 antibodies activate antigen-presenting cells, such as dendritic or B cells, to prime tumor-specific T cell responses, effectively “pushing the gas” on the immune system to make it work harder. This “lead-in” therapy, which is being investigated in clinical trials around the world, including at Penn Medicine, has been shown to turn so-called “cold” tumors hiding from the body’s defenses into “hot” ones by “priming” the T cells before other treatments.
Think of the body’s immune response like an assembly line, with points A, B, C, D, and E, that kill the tumor at the end, Vonderheide said. For example, a T cell starts, it expands, it gets exhausted, and stops because of the PD-1 pathways. Checkpoint inhibitors take that brake off toward the end, so the T cells can then attack the tumor.
“We’ve been drugging the very last step,” said Vonderheide, who serves as a principal investigator on several CD40 combination trials at Penn, including a national trial through the Parker Institute of Cancer Immunotherapy. “In many patients, however, that won’t work because points A through E hasn’t happened. You can give them a checkpoint inhibitor, but there are no T cells to take the brakes off.”
Cancer Cell, Volume 33, Issue 4
“With the CD40 drugs, we’re back at point A to prime the T cells in the body to continue on in the immune response,” he added. “Once you get A going, you can potentially treat more patients.”
CD40 agonists have moved successfully from preclinical studies, many of which have been conducted by Penn researchers, where they have demonstrated anti-tumor activity, especially in combination with checkpoint inhibitors and chemotherapy, into human trials in recent years.
There are currently four clinical trials being conducted at Penn, including:
- A Phase I study, led by Vonderheide, to learn if adding the investigational anti-CD40 drug RO7009789 to nab-paclitaxel and gemcitabine both before surgery and after surgery is safe, feasible, and beneficial to patients with pancreatic cancer.
- A Phase 1b/2 study to evaluate the efficacy of the combinations of APX005M, Nivolumab, Gemcitabine, and nab-Paclitaxel or APX005M, Gemcitabine, nab-Paclitaxel in treating patients with metastatic pancreatic adenocarcinoma. The principal investigator is Mark O’Hara, MD, an assistant professor of Hematology Oncology.
- Using the immuno-activating monoclonal antibody called APX005M, administered in combination with nivolumab to adults with metastatic melanoma. The Phase 1/2 trial is led by Gerald P. Linette, MD, PhD, the chief medical officer for Cancer Immunotherapy and clinical director of the Sean Parker Institute.
- A study of the anti-CD40 drug APX005M in adults with solid tumors. The principal investigator is Dr. Ronac Mamtani, MD, MSCE, an assistant professor of Hematology Oncology.
Additionally, Abramson Cancer Center researchers are planning trials using this approach in patients with advanced and metastatic solid tumors.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $8.9 billion enterprise.
The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $496 million awarded in the 2020 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center—which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report—Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is powered by a talented and dedicated workforce of more than 44,000 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2020, Penn Medicine provided more than $563 million to benefit our community.